STOCK TITAN

Personalis (PSNL) CFO exercises options, sells 1,201 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Personalis, Inc. insider trading report: Chief Financial Officer and Chief Operating Officer Aaron Tachibana exercised stock options for 1,201 shares of common stock at $9.16 per share on January 22, 2026, then sold 1,201 shares of common stock at $11.50 per share the same day. After these transactions, he held 164,458 shares of common stock directly and 107,631 stock options. The filing notes that the sale and option exercise were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2025, which is designed to allow insiders to trade shares according to a set schedule.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tachibana Aaron

(Last) (First) (Middle)
C/O PERSONALIS, INC.
6600 DUMBARTON CIRCLE

(Street)
FREMONT CA 94555

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Personalis, Inc. [ PSNL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO AND COO
3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/22/2026 M(1) 1,201 A $9.16 165,659 D
Common Stock 01/22/2026 S(1) 1,201 D $11.5 164,458 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $9.16 01/22/2026 M(1) 1,201 (2) 03/13/2029 Common Stock 1,201 $0 107,631 D
Explanation of Responses:
1. The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2025.
2. The shares subject to the option are fully vested and exercisable.
/s/ Aaron Tachibana 01/23/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider trading Personalis (PSNL) shares in this Form 4?

The reporting person is Aaron Tachibana, who serves as CFO and COO of Personalis, Inc.

What transactions did Aaron Tachibana report in Personalis (PSNL) stock?

On January 22, 2026, he exercised options for 1,201 shares of common stock at $9.16 per share and then sold 1,201 shares of common stock at $11.50 per share.

How many Personalis (PSNL) shares does the CFO own after these transactions?

Following the reported trades, Aaron Tachibana directly owned 164,458 shares of common stock and held 107,631 stock options.

Were the Personalis (PSNL) insider trades under a Rule 10b5-1 plan?

Yes. The option exercise and sale were effected under a Rule 10b5-1 trading plan that Aaron Tachibana adopted on August 7, 2025.

What is the nature of ownership for the reported Personalis (PSNL) shares?

The Form 4 indicates that the reported holdings and transactions are directly owned by Aaron Tachibana, with no indirect ownership entity listed.

Are the stock options reported by the Personalis (PSNL) CFO fully vested?

Yes. A footnote states that the shares subject to the option are fully vested and exercisable.

Personalis

NASDAQ:PSNL

PSNL Rankings

PSNL Latest News

PSNL Latest SEC Filings

PSNL Stock Data

999.05M
58.15M
31.36%
52.26%
9.19%
Diagnostics & Research
Services-medical Laboratories
Link
United States
FREMONT